

CURRENT STRATEGIES IN DEVELOPMENT OF NEW CHROMONE DERIVATIVES WITH DIVERSIFIED PHARMACOLOGICAL ACTIVITIES: A REVIEW

Noor ul Amin Mohsin,^{1,*} Muhammad Irfan,² Shams ul Hassan,² and Usman Saleem²

Original article submitted November 30, 2019.

Chromone derivatives possess a spectrum of biological activities. Chromone has been recognized as a privileged structure for new drug invention and development. Substitution pattern of chromone scaffold determines different type of biological activities. The type, number and position of substituents connected to the chromone core play a vital role in determining pharmacological activities. In the present review, we have discussed new chromone derivatives as anticancer, anti-diabetic, antimicrobial, anti-inflammatory, antioxidant and as anti-Alzheimer agents. This review deals with the chromone derivatives prepared by combining chromone molecule with various natural and synthetic pharmacophores and pharmacological activities presented by them. The main aim is to highlight the diversified pharmacological activities exhibited by chromone hybrid molecules during the last eight to ten years.

Keywords: chromones; anticancer; antimicrobial; anti-Alzheimer; anti-inflammatory; antioxidant, anti-diabetic.

1. INTRODUCTION

Chromone is a heterocyclic compound containing oxygen as heteroatom and has a benzo- γ -pyrone skeleton (Fig. 1, compound **1**). Chromone is a natural molecule present in the diet of human and animals and shows less toxicity to mammalian cells [1]. Chromone containing natural and synthetic molecules displayed interesting biological activities [2]. Medicinal properties exhibited by chromone derivatives are antibacterial, antifungal, antioxidant, antimalarial, neuroprotective and HIV inhibitory potential [3 – 8]. Chromone derivatives have also shown promising anticancer and antiviral potential [9 – 13]. Anti-inflammatory, antiallergenic and antiulcer are other properties displayed by chromone derived molecules [14 – 16]. Chromone is treated as an attractive source for the synthesis of new drugs due to its valuable activities and low toxicity [17]. Chromone is considered as a single molecule which can combine with different types of receptors [18]. Modifications of chromone scaffold have been performed at benzene or pyrone ring by attachment of

different substituents. 3-Formylchromone (Fig. 1, compound **2**) is a frequently used precursor for the synthesis of chromone derivatives and can be prepared easily by the Vilsmeier – Haack reaction [19].

2. CHEMISTRY AND PHARMACOLOGY OF NEW DRUGS BASED ON CHROMONE SCAFFOLD

Chromone derived molecules have been discussed with respect to chemical structures, pharmacological activities and structure – activity relationship (SAR) in following sections.

2.1. Chromone Derivatives as Anticancer Agents

Cancer is a serious problem all around the world due to high mortality and there is demand to discover new leads as anticancer agents [20]. A number of anticancer drugs have been discovered from natural sources [21]. Chromone derived molecules have displayed excellent anticancer activities. Amin and co-workers synthesized new molecules by merging benzofuran and 5*H*-furo[3,2*g*]chromone-5-one and attached different heterocyclic rings through sulfonamide group. These compounds displayed *in vitro* activity against breast cancer cell line (MCF-7) ranging from 0.004 –

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000 Pakistan.

² Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, 38000 Pakistan.

* e-mail: noorulaminmohsin@yahoo.com

0.87 μM . Compound **3** (Fig. 2) presented prominent *in vitro* activity ($\text{IC}_{50} = 0.056 \pm 0.0027 \mu\text{M}$) against MCF-7 cell line in comparison to standard drug (doxorubicin, $\text{IC}_{50} = 0.62 \pm 0.0316 \mu\text{M}$) and proved less toxicity to normal cell line ($\text{IC}_{50} = 23 \pm 1.02 \mu\text{M}$). These derivatives also showed p38 α MAPK (mitogen-activated protein kinase) inhibition activity. MAPK controls many biological functions such as cell growth, differentiation and inflammation [22]. Molecular docking studies showed that compound **3** formed four hydrogen bonds with K-53, M-109 and G-170 amino acids of MAPK [23]. Singh, et al. attached indole, pyrimidine, pyrazole with chromone to produce new derivatives. It was observed that introduction of 2,6-dichlorophenyl, 2,6-dichlorobenzoyl group along with indolinone produce notable activities. Compound **4** manifested prominent *in vitro* antitumor activity with 50 – 90% growth inhibition of all tumor cell lines and showed an average GI_{50} value of 3.2 μM . Compound **4** was more potent against leukemia (RPMI-8226 $\text{GI}_{50} = 1.2 \mu\text{M}$, SR $\text{GI}_{50} = 1.4 \mu\text{M}$) cell line, colon (HCT-15, $\text{GI}_{50} = 0.6 \mu\text{M}$), prostate (PC-3, $\text{GI}_{50} = 1.3 \mu\text{M}$), CNS (U251, $\text{GI}_{50} = 1.4 \mu\text{M}$) and melanoma cancer cell lines (LOX-IMVI, $\text{GI}_{50} = 1.5 \mu\text{M}$) [24]. Synthesis of chromone and sulfonamide comprising molecules was carried out by Awadallah, et al. in which two molecules were linked to each other by a large heterocyclic ring or by small linker groups such as methine amine or alkyl amine. Compound separated by small linker group dispensed greater activity. Upon *in vi-*




Fig. 1. Structural formulas of (1) chromone and (2) 3-formyl chromone.

tro evaluation, Compound **5** emerged as the most active against breast (MCF-7, $\text{IC}_{50} = 0.72 \mu\text{M}$) and lung (A-549, $\text{IC}_{50} = 0.50 \mu\text{M}$) cancer cell lines as compared to doxorubicin (MCF-7 $\text{IC}_{50} = 33.13 \pm 2.90 \mu\text{M}$, A-549 $\text{IC}_{50} = 26.81 \pm 2.50 \mu\text{M}$). Compound **5** presented selectivity for isoforms IX and XII of the human carbonic anhydrase (hCA). This compound induced apoptosis in both types of cancer cell. It was also observed that compounds having free sulfonamide group presented higher activity. When the sulfonamide group was attached with heterocyclic scaffold such as pyridine, pyrimidine, and isoxazole, less active derivatives were obtained [25]. Chen, et al. attached chromone molecule to 1-alkyl-1H-imidazole-2-yl via dienone as linker group. The nitrogen-containing heterocycles were used as bioisostere for phenols in the natural compound while the dienone linker was used as substitute for dienone in




Fig. 2. Chromone derived molecules **3** – **9** as anticancer agents.

curcumin. Compound **6** presented excellent activity against prostate cancer (PC-3, $IC_{50} = 1.8 \pm 0.3 \mu\text{M}$ and LNCaP $IC_{50} = 1.0 \pm 0.2 \mu\text{M}$) cell lines. The nitrogen atom of imidazole carries ethyl group. Replacement of ethyl group by longer chain has no significant influence on anticancer activity. Therefore they are excellent molecules for future investigations [26]. Dolatkhah, et al. used the three-component reaction involving chromone-3-carboxaldehyde, alkyl acetoacetate, urea or thiourea to produce 4H-chromone-1,2,3,4-tetrahydropyrimidine-5-carboxylates using MCM-41-SO₃H nanoparticles as catalyst. The catalyst can be recycled and reused. Compound **7** presented prominent activity against leukemia cell line upon evaluation by microculture tetrazolium test (MTT) assay. This compound showed no toxicity to normal cell line human foreskin fibroblast (Hu02). Compound **5** showed high affinity (binding energy = -10.10 kcal/mol) with Abl-kinase enzyme by Autodock-4 program [27]. Nam, et al. developed chromone derived analogues of lavendustin. Upon anticancer evaluation, compounds **8** ($IC_{50} = 6.01 \pm 2.7 \mu\text{M}$) and **9** ($IC_{50} = 9.92 \pm 3.6 \mu\text{M}$) showed prominent activities against A-549 cell line. Compound **8** ($IC_{50} = 6.89 \pm 2.6 \mu\text{M}$) and **9** ($IC_{50} = 7.86 \pm 2.2 \mu\text{M}$) also showed activity against HCT-15 cell lines. In compound **8**, replacement of 4-methoxybenzyl with benzyl or phenethyl decreased the activity. In compound **9**, replacement of 4-nitrobenzyl with 4-methoxybenzyl or benzyl group produced less active compounds against HCT-15 cell line [28].

Bhatia and co-workers synthesized chalcone-chromone derived molecules. Upon *in vitro* evaluation, compound **10** (Fig. 3) showed prominent activity (87% growth inhibition) against colon cancer cell line (HCT-116) as compared to fluorouracil (67% inhibition). Compound **10** carries two halogen atoms each on the chromone core and chalcone fragment [29]. Ozen, et al. conjugated chromone molecule with 5-membered heterocyclic scaffolds thiazolidinones, imidazolidinones and thiohydantoin to produce new hybrid molecules. Compound **11** showed prominent activity against liver (Huh-7 $IC_{50} = 5.2 \mu\text{M}$) and breast cancer (MCF-7, $IC_{50} = 4.9 \mu\text{M}$) cell lines. This compound contains unsubstituted chromone while ethyl group is attached with thiohydantoin. When the chromone ring is substituted with methyl group, resultant compound showed less activity. Compound **11** did not show apoptosis but only reduced the replication of cells [30]. Singh and co-workers synthesized chromenopyridine derivatives based on the activity of chromones and pyridones. Derivatives bearing electron withdrawing groups at positions # 5, # 6 and # 7 of chromone scaffold showed better activity. Compound **12** appeared as the most potent against PC-3 ($IC_{50} = 2.4 \pm 3.4 \mu\text{M}$), MCF-7 ($IC_{50} = 10.7 \pm 2.5 \mu\text{M}$) and Hela ($IC_{50} = 7.0 \pm 3.5 \mu\text{M}$) cancer cell lines. This compound contains allyl group attached to pyridone and showed better activity as compared to unsubstituted compounds [31]. Obrique-balbua and co-workers synthesized chromone derivatives as ABCC1 modulators. An amino or carboxamide group was introduced at

position # 2. ABCC1 overexpression is detected in different types of cancers. Compound **13** was the most effective ($IC_{50} = 11.3 \pm 1.8 \mu\text{M}$) in reducing the ABCC1 mediated resistance in comparison to reversan ($IC_{50} = 4.3 \pm 0.2 \mu\text{M}$). Derivative **13** showed selectivity for ABCC1 over ABCG2 and ABCB1. It consists of chromone molecule connected to benzo[1, 2, 5]oxadiazole via piperazine linker group. Insertion of carbonyl group between chromone and piperazine decreased the activity [32]. Abdelhafez et al. synthesized benzofuran derivatives as vascular endothelial growth factor (VEGF) inhibitor. Bromovisnagin (**14**) was an intermediate product and consist of chromone core in its structure. Bromovisnagin (**14**) showed prominent anticancer ($IC_{50} = 3.67 \times 10^{-7} - 7.65 \times 10^{-13} \mu\text{M}$) potential as compared to other products in this series. Compound **14** was the most potent agent against MCF-7 ($IC_{50} = 3.67 \times 10^{-7}$) as compared to standard drug epirubicin ($IC_{50} = 2.22 \times 10^{-9}$). Docking studies of compound **14** with VEGFR2 (vascular endothelial growth factor receptor) kinase enzyme showed hydrogen bonding between furan oxygen and amino group of D1046. Methoxy group showed interaction with NH moiety of K868 [33]. Chand and colleagues synthesized substituted chromone, 4-oxo-4H-1-benzopyran derivatives as anticancer agents. Compounds having acrylate group at position # 3 demonstrated prominent activity. Derivatives having amide and acid group at this position proved less active. Compound **15** was the most active (50 – 60% inhibition) agent against colon (HT-29), breast (SK-OV-3) and ovarian (MDA-468) cell lines as compared to doxorubicin (80% inhibition). Compound **15** did not show *in vitro* Src kinase inhibitory activity ($IC_{50} < 300 \mu\text{M}$) as compared to staurosporin ($IC_{50} = 0.6 \mu\text{M}$) [34]. Han and colleagues synthesized succinimide derivatives by C-H functionalization of chromone, naphthoquinone and xanthone scaffolds with maleimide scaffold. Chromone derivatives (**16a, b, c**) showed only minute activity ($IC_{50} < 50 \mu\text{M}$) versus MCF cell line [35]. EL-Garah, et al. synthesized chromone carboxamide derivatives. Compound **17** presented prominent activity ($IC_{50} = 0.9 \mu\text{M}$) against MCF-7 cancer cell line in comparison to tamoxifen ($IC_{50} = 0.39 \pm 0.01 \mu\text{M}$). Structure activity relationship (SAR) studies highlighted that attachment of fluorine atom at position # 6 of chromone core produced more active derivatives. Replacement of fluorine atom by chloro and methyl groups produced less active derivatives. The presence of propyl side chain at the amide group also increased the activity. Compound **18** also presented in-vitro anti-inflammatory activity (79.9 ± 6.6% inhibition) as lipoxigenase (LOX) inhibitor. Derivatives having hydrophilic group showed better anti-inflammatory activity [36]. Ali, et al. synthesized chromone annulated phosphorous heterocycles as anticancer agents. Phosphorous reagents used in the synthesis were phosphorous halides, phosphorous sulfides and phosphonic acid. Anticancer activity was evaluated by using crystal violet blue assay. Compounds **19** and **20** exhibited prominent




Fig. 3. Chromone derivatives 10 – 20 as anticancer agents.

activities against HepG-2 ($IC_{50} = 1.61 \mu\text{g/mL}$, $IC_{50} = 2.49 \mu\text{g/mL}$) and HCT-116 ($IC_{50} = 1.72 \mu\text{g/mL}$, $IC_{50} = 1.56 \mu\text{g/mL}$) as compared to doxorubicin (Hep-G-2 $IC_{50} = 0.467 \mu\text{g/mL}$, HCT-116 $IC_{50} = 0.468 \mu\text{g/mL}$). The thiophosphoryl (P=S) bond was described as major cause of cytotoxicity of these compounds as compared to phosphoryl group (P=O) [37].

Sun, et al. carried out synthesis of thiopyrano[4,3-d]pyrimidine derivatives having chromone molecules. Compound 21 displayed significant inhibition of mTOR ($IC_{50} = 1.10 \pm 0.10 \mu\text{M}$) and p13 α ($IC_{50} = 0.92 \pm 0.12 \mu\text{M}$) kinases. Compound 21 (Fig. 4) displayed marvelous *in vitro* activity against MCF-7 ($IC_{50} = 11.8 \pm 6.9 \mu\text{M}$), HeLa ($IC_{50} = 10.3 \pm 0.58 \mu\text{M}$) and HepG2 ($IC_{50} = 8.77 \pm 0.83 \mu\text{M}$) cancer cell lines as evaluated by MTT assay. Docking investigation with mTOR and p13 α kinases highlighted that morpholine, chromone and hydrazinyl groups are essential for antitumor activities. Substitution on the chromone nucleus manifested significant influence on activity. Introduction of carboxylic group on the chromone core proved more active as compared to methyl, ethyl and hydroxyl group [38]. Abu-Aisheh, et al. synthesized amidrazone derivatives having flavone scaffold. Upon evaluation as anticancer agents by MTT assay, compounds 22 ($IC_{50} = 1.42 \pm 0.13 \mu\text{M}$) and

23 ($IC_{50} = 2.92 \pm 0.94 \mu\text{M}$) showed prominent *in vitro* activity versus breast cancer cell line (T47D) as compared to doxorubicin ($IC_{50} = 0.33 \pm 0.05 \mu\text{M}$). Replacement of piperazine ring by piperidine produced less active agents against breast cancer. Derivatives having phenyl group at position # 2 presented higher activity as compared to methyl group. These compounds can be good candidates as anticancer agents [39]. Singh, et al. synthesized chromone and isoxazolidine based compounds by regioselective and stereoselective 1,3-dipolar cycloaddition reaction. Compound 24 ($IC_{50} = 0.7 \mu\text{M}$) exhibited prominent *in vitro* activity against A549 cell line in comparison to paclitaxel ($IC_{50} = 0.4 \mu\text{M}$). This compound bears disubstituted isoxazolidine scaffold. This compound also induced apoptosis in HL-60 cancer cell line [40]. Satyajit Singh and co-workers synthesized chromone piperidine fused isoxazolidine molecules. Derivatives having electron withdrawing groups at the chromone core presented superior activity. Compounds having aromatic ring attached with isoxazolidine presented better activity. Compound 25 showed prominent *in vitro* cytotoxicity against COLO ($IC_{50} = 12.6 \mu\text{M}$) as compared to fluorouracil ($IC_{50} = 21 \mu\text{M}$). Compound 25 also exhibited moderate activity against IMR-32 ($IC_{50} = 55.2 \mu\text{M}$) as compared to adriamycin ($IC_{50} = 1.7 \mu\text{M}$). Compound 26




Fig. 4. Chromone derivatives 21 – 29 as anticancer agents.

($\text{IC}_{50} = 10.7 \mu\text{M}$) presented prominent activity against neuroblastoma (IMR-32) cell line [41]. Zwergel and co-workers synthesized chromone and coumarin based benzofuran derivatives. Biological evaluation on human leukemia (k562) cell line was carried out. Compounds 27 and 28 exhibited prominent activities having 72% and 63% cell survival respectively by using $50 \mu\text{M}$ concentrations. Compound 27 showed 24% apoptosis. Substitution on chromone nucleus does not have significant influence on activity. Replacement of benzofuran by naphthofuranone produced more active compound towards apoptosis [42]. Zhu, et al. designed and synthesized thienopyrimidine and chromone derived compounds as mTOR/P13K α inhibitors [43]. Compound 29 ($97.2 \pm 0.4\%$ inhibition) presented prominent activity against mTOR/P13K α kinase. Derivative 29 also manifested notable *in vitro* activity versus H460 ($\text{IC}_{50} = 1.2 \pm 0.3 \mu\text{M}$) and PC-3 ($\text{IC}_{50} = 0.85 \pm 0.04 \mu\text{M}$) cell lines in comparison to positive control ($\text{IC}_{50} = 9.52 \pm 0.29 \mu\text{M}$, $\text{IC}_{50} = 16.27 \pm 0.54 \mu\text{M}$ against H-460 and PC-3). Chromone molecule having carboxylic acid or nitro group was found to be optimum for the activity in this series. Docking studies revealed that chromone molecule is vital for activity. Carboxylic group of chromone interacted via hydrogen bonding with TRP-2239 and ARG-2348. Morpholine group formed hydrogen bonding with VAL-2240 [44].

2.2. Chromone Derivatives as Antidiabetic Agents

Diabetes Mellitus is caused by the elevated level of glucose in the blood due to improper production of insulin. It is

a very common problem all around the world [45]. Currently available anti-diabetic drugs are linked with various side effects [46]. Anti-diabetic properties of chromone derivatives are described in this section. Ceylan-unlusoy, et al. attached chromone scaffold with 2,4-imidazolidindione and 2,4-thiazolidindione. Attachment of heterocyclic rings at position # 3 produced more active derivatives as compared to position # 2. Compounds 30 ($142.7 \pm 17.60\%$) and 31 ($155.4 \pm 35.16\%$) (Fig. 5) showed prominent *in vitro* insulinotropic potential with dose of $1 \mu\text{g/mL}$ as compared to standard drug glibenclamide ($138 \pm 13.99\%$). Incorporation of methyl and ethyl group in the heterocyclic ring showed comparable activity to unsubstituted derivatives [47]. Later on, Ceylan-unlusoy, et al. synthesized chromone derivatives having imidazolidindione, 2,4-thiazolidindione and 2-thioxoimidazolidine-4-one heterocyclic cores. Derivatives having substituted 2,4-thiazolidindione ring demonstrated better activity and the most active agent carries methyl group at heterocyclic nitrogen. Therefore lipophilic groups at the heterocyclic nitrogen were found significant for increasing the activity. Compound 32 (dose = $0.001 \mu\text{g/mL}$) was the most prominent which increased the release of insulin ($120.6 \pm 13.53\%$) as compared to glibenclamide ($145.7 \pm 7.74\%$) [48]. Wang, et al. linked chromone to the benzene sulfonamide through hydrazone linkage to produce new α -glucosidase inhibitors. The α -glucosidase enzyme is involved in the hydrolysis of carbohydrates and releases glucose. Compound 33 showed excellent *in vitro* inhibition ($\text{IC}_{50} = 20.1 \pm 0.19 \mu\text{M}$) of this enzyme in comparison to




Fig. 5. Chromone derivatives 30 – 37 as antidiabetic agents.

acarbose ($IC_{50} = 817.38 \pm 6.27 \mu\text{M}$). Compound **33** carries a free sulfonamide group attached to the phenylhydrazone. Replacement of phenylhydrazone by benzohydrazone and benzene ring by thiophene ring produced less active molecules. Compound **33** displayed non-competitive inhibition as determined by Lineweaver-Burk plot. In molecular docking studies, hydrogen bonding was observed between the drug molecule and Asp-214 and Arg-439 of enzyme [49]. One year later, Wang, et al. synthesized hybrid molecules comprising chromone-isatin as α -glucosidase inhibitors. These molecules exhibited excellent *in vitro* blockage of this enzyme and compound **34** ($IC_{50} = 3.18 \pm 0.12 \mu\text{M}$) appeared as the most potent in this series. Substitution on the chromone core was very important where introduction of hydroxyl group significantly enhances the activity. Molecular docking studies also showed interaction (binding energy = -8.8 kcal/mole) of this compound with the glucosidase enzyme. 4-Bromophenyl moiety showed hydrophobic interactions with Phe-157 and Phe-177, Ala-278 and Phe-300. Benzopyrone formed δ - δ interaction with Phe-300. Hydroxyl group formed hydrogen bonding with Gln-350 [50]. Alpha-amylase is an enzyme involved in the hydrolysis of carbohydrates. Salar, et al. connected chromone to hydrazinyl thiazole to produce the new hybrid molecules. Upon *in vitro* evaluation as the α -amylase inhibitors, Compound **35** showed prominent inhibition ($IC_{50} = 2.826 \pm 0.06 \mu\text{M}$) of this enzyme in comparison to acarbose ($IC_{50} = 1.9 \pm 0.07 \mu\text{M}$). Compound **35** showed a docking score of -7.1717 and π - π interactions with TRP-59 of α -amylase. Compound **35** also exhibited DPPH (2,2-diphenyl-1-picrylhydrazyl) ($IC_{50} = 1.13 \pm 0.15 \mu\text{M}$) and

ABTS (2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) ($IC_{50} = 1.083 \pm 0.15 \mu\text{M}$) radical scavenging activities. Compound **35** bears unsubstituted phenyl ring with thiazole. Replacement of phenyl group with biphenyl core also produced more active compounds. Incorporation of hydroxyl group at the aromatic ring decreased the activity. Dichloro-substituted derivatives at the aromatic ring produced more active compounds as compared to mono-substituted compounds. Attachment of methyl group with chromone core also produced less active derivatives [51]. Parthiban, et al. synthesized quercetin based chromone derivatives as alpha-amylase inhibitors. Various modifications in the chromone core of quercetin were carried out such as introduction of furan and indole ring. Compounds **36** ($IC_{50} = 13 \pm 0.16 \mu\text{M}$) and **37** ($IC_{50} = 12 \pm 0.14 \mu\text{M}$) presented prominent *in vitro* activities as alpha amylase inhibitor as compared to quercetin ($IC_{50} = 22 \pm 0.01 \mu\text{M}$). In these derivatives chromone core is attached with indole ring. Derivatives having aliphatic side chains at the indole nitrogen presented higher activity as compared to aromatic rings. Molecular docking studies showed that chromone core forms hydrophobic interaction with Trp58, Tyr62 and Leu165. Diethylamino group of compound **37** interacted via hydrogen bonding as well as hydrophobic interaction with Glu233 and Ile235. These derivatives have the potential for further investigations as anti-diabetic agents [52].

2.3. Antimicrobial Activity of Chromone Derived Molecules

Parasites such as bacteria, viruses, fungi, protozoa, trypanosomes, etc. cause various diseases in human beings and are responsible for high mortality and morbidity [53].




Fig. 6. Chromone derivatives **38** – **45** as antimicrobial agents.

Chromone derivatives have also displayed antimicrobial activities. Bathini and co-workers synthesized chromone-2,3-dihydroquinazolin-4-one molecules in which dihydroquinazolinone was attached at position # 2. Compounds **38** and **39** (Fig. 6) were most active against *Staphylococcus aureus* (*S. aureus*) (MIC = 62.5 µg/mL) and *Escherichia coli* (*E. coli*) (MIC = 62.5 µg/mL) in comparison to ciprofloxacin (MIC = 25 – 50 µg/mL). Compound **40** presented antifungal activity (MFC = 200 µg/mL) against *Candida albicans* (*C. albicans*) as compared to griseofulvin (MFC = 500 µg/mL). Derivatives bearing halogen atoms at the chromone core displayed excellent activities [54]. Coa, et al. synthesized quinoline-chromone hybrid molecules as anti-leishmanial and antitrypanosomal agents. Although compound **41** demonstrated noticeable activities against *Trypanosoma cruzi* (*T. cruzi*, $EC_{50} = 4.09 \pm 0.24$ µM), *Leishmania panamensis* (*L. panamensis*, $EC_{50} = 6.11 \pm 0.26$ µM) respectively but it was masked by greater cytotoxicity ($LC_{50} = 5.4 \pm 0.9$ µM) for mammalian U937 cells [55]. After one year, antiprotozoal hybrid molecules of chromones, quinoline and imidazole with furanchalcone were developed by Garcia, et al. Among these derivatives, chromone derived compounds did not show promising activity and also proved cytotoxic. Compound **43** displayed moderate *in vitro* activity against *T. cruzi* ($EC_{50} = 25.58 \pm 1.34$ µM, SI = 1.07) as compared to standard drug benznidazole ($EC_{50} = 40.3 \pm 6.92$ µM, SI = 17). Compounds **42** ($EC_{50} = 44.02 \pm 4.90$ µM, SI = 0.69) and **43**

($EC_{50} = 46 \pm 4.77$ µM, SI = 0.59) demonstrated moderate activity against *L. panamensis* as compared to standard drug meglumine antimonate ($EC_{50} = 25.68 \pm 5.74$ µM). Compounds containing alkyl chain of 8 or 9 carbon atoms between chromone and furanchalcone presented higher activity [56]. Otero, et al. synthesized hybrid molecules of triclosan with chromone, coumarin and chalcone. Among the chromone derivatives, compound **44** ($EC_{50} = 2.7 \pm 0.4$ µM, SI = 2.4) was found to be most active as compared to meglumine antimonate ($EC_{50} = 6.3 \pm 0.9$ µM, SI = 78.7) upon *in vitro* evaluation. Compound **44** also presented *in vitro* cytotoxicity ($LC_{50} = 6.4 \pm 0.8$ µM) for mammalian cell line U937. Therefore the increased anti-leishmanial activity was shrouded by the corresponding increase in the cytotoxicity. SAR studies showed that increase in chain length between two pharmacophores produced less active compounds [57]. Lersirisuk, et al. evaluated some chromone derivatives as anti-plasmodial agents which were previously recognized as protease inhibitors. These derivatives are substituted at position # 2 and position # 3. Compound **45** exhibited prominent activity ($IC_{50} = 0.95$ µM) against *Plasmodium falciparum* K1 (multidrug-resistant strain) as compared to standard drug primaquine ($IC_{50} = 2.41 \pm 13$ µM). In molecular docking studies against plasmesin II (an aspartic protease involved in hemoglobin degradation), compound **45** exhibited binding free energy of -13.24 kcal/mol. 2-Nitrophenyl and 4-nitrobenzoyl and 4-nitrophenyl groups are directed towards hydrophobic




Fig. 7. Chromone derivatives **46** – **64** as antimicrobial agents.

pocket comprising Ile32, Phe111, Ile123 and Val78, Ile290, Leu292, Ile300. Hydroxyl groups interacted via hydrogen bonding with the carbonyl oxygen of Asn76 [58].

Nalla, et al. used click chemistry technique to attach chromone to the 1,4-disubstituted [1, 2, 3]triazole [59]. New hybrid molecules showed *in vitro* antimycobacterial activity and compound **46** (Fig. 7) emerged as the most potent (MIC = 1.56 $\mu\text{g/mL}$) as compared to rifampicin (MIC = 0.24 $\mu\text{g/mL}$). In molecular docking investigations, compound **46** (binding energy = -11.123 kcal/mol) showed interaction with enoyl-acyl carrier protein reductase enzyme, of *Mycobacterium tuberculosis* (*M. tuberculosis*). Compound **46** presented interaction with Asp-64, Trp-222 and Try-158 of the enzyme. Substituents at triazole ring played a crucial role in the activity and aromatic group presented less activity as compared to aliphatic substituents. The most active compound carries a long aliphatic chain attached with triazole scaffold. Further investigation revealed that this compound follows the Lipinski rule of five and possesses drug-like properties [60, 61]. Singh, et al. synthesized 3-furano-chromone derivatives. Upon investigation as *in vitro* anti-tubercular agent, these compounds (**47** – **50**) demonstrated moder-

ate activity (10 – 12 $\mu\text{g/mL}$) against sensitive H37Rv as compared to ethambutol (2 $\mu\text{g/mL}$) and streptomycin (2 $\mu\text{g/mL}$). It was assumed that these compounds act on the lipoprotein part of the cell wall of *Mycobacterium tuberculosis* [62]. Cano, et al. synthesized fluorine-containing chromone and tetrazole hybrid molecules by Ugi-azide reaction [63]. These derivatives displayed moderate antimicrobial activity as is evident by compound **51** (MIC = 20 $\mu\text{g/mL}$) activity versus *Pseudomonas aeruginosa* (*P. aeruginosa*) as compared to cefotaxime (MIC = 0.5 $\mu\text{g/mL}$). Compound **52** also displayed low antiamebic activity (IC₅₀ = 61.7 $\mu\text{g/mL}$) as compared to metronidazole (IC₅₀ = 1.5 $\mu\text{g/mL}$). Compound **53** exhibited antifungal activity against *Sporothrix schenckii* (*S. schenckii*) at the concentration of 6.25 $\mu\text{g}/\mu\text{L}$. Introduction of halogen atoms at the chromone core produced more active derivatives as compared to non-halogenated derivatives [64]. Reddy, et al. produced the fused hybrid molecules by reacting 2-amino chromone, benzaldehyde, 1,4-dimedone to produce chromeno-tetrahydroquinoline. Antibacterial activity was tested against *P. aeruginosa*, *S. aureus*, *E. coli* and *Bacillus subtilis* (*B. subtilis*). In these derivatives, tetrahydropyridine is embed-

ded in dimedone and chromone scaffolds. Agar well diffusion method was used for assessing antibacterial activity. Compounds **54**, **55** and **56** were most active derivatives (ZOI = 22 – 37 mm) as compared to streptomycin (ZOI = 25 – 40 mm) against these bacteria. Derivatives bearing small alkyl chains demonstrated better activity. Introduction of cyclic rings e.g. cyclopropyl, cyclobutyl and cyclopentyl at this position produced less active derivatives [65]. Pouramiri, et al. synthesized 1-aryl-3-amino-N-benzyl-1H-benzo[f]chromeno-2-carboxamide derived compounds as antibacterial agents. Compound **57** (MIC = 1.56 mg/mL), **58** (MIC = 1.56 mg/mL) and **59** (MIC = 0.78 mg/mL) presented prominent activity against *P. aeruginosa*. Compounds **57** (MIC = 3.125 mg/mL) and **59** (MIC = 1.56 mg/mL) presented excellent antifungal activity against *C. albicans* [66]. Tiwari and co-workers synthesized chromone and pyrimidine hybrid molecules by applying green chemistry procedure. Upon *in vitro* antibacterial evaluation, compounds **60** (MIC₁₀₀ = 14 µg/mL) and **61** (MIC₁₀₀ = 16 µg/mL) manifested activity against *E. coli* 1411 as compared to cycloserine (MIC₁₀₀ = 16 µg/mL). Compound **62** showed outstanding antifungal activity against *Aspergillus flavus* (*A. flavus*, MIC = 15 µg/mL), *Aspergillus niger* (*A. niger* MIC = 16 µg/mL) and *Cryptococcus neoformans* (*C. neoformans* MIC = 15 µg/mL) as compared to standard drug miconazole (MIC₁₀₀ = 12 µg/mL) respectively. Compound **62** carries electron-donating group at the chromone core and proved more active as compared to other derivatives having fluorine and methyl groups. Compound **62** possesses a sulfur atom and hydrazine groups at the pyrimidine ring. Compound **62** showed a binding score of -7.24 and it formed hydrogen bonding interaction with Tyr-173 and Hem-500 of lanosterol 14- α demethylase enzyme of *C. albicans*. Pharmacokinetic analysis proved that these derivatives possess decent drug-like properties [67]. Li, et al. attached chromone with pyrazole heterocyclic scaffold through a flexible chain to produce nematocidal agents. Two pharmacophores were linked through amide and alkyl ester groups. Upon *in vivo* evaluation, derivatives **63** and **64** showed excellent activity (100%) against *Meloidogyne incognita* by using concentrations 10 mg/mL and 25 mg/mL. Standard drug tioxazafen exhibited 100% inhibition at 25 mg/mL and 92.9% at 10 mg/mL. SAR studies revealed that incorporation of methyl, ethyl and phenyl groups in the linker chain produced less active derivatives. Attachment of trifluoromethyl group at position # 3 of pyrazole scaffold produced more active derivatives as compared to bromide, cyanide and methyl groups [68].

Siddiqui, et al. synthesized prazolyl pyranopyridines derivatives by the reaction of 3-acetoacetyl benzopyranopyridone with different hydrazine derivatives. Benzopyranopyridones contain condensed chromone ring and are the intermediate products in this series. Among these derivatives, compound **65** (Fig. 8) manifested prominent activity against *Salmonella typhi* (*S. typhi*, ZOI = 12 mm), *Salmonella*

dysenteriae (*S. dysenteriae*, ZOI = 19 mm) and *Klebsiella pneumoniae* (*K. pneumoniae*, ZOI = 18 mm) as compared to chloramphenicol (ZOI = 16 mm, 23 mm, 23 mm against these bacteria) [69]. Batula, et al. synthesized aryl isoxazole and 6-fluorochromone carboxylate derivatives in which both these scaffolds were linked by ester linkage. The introduction of aryl groups at the isoxazole core enhanced the antibacterial activity. Compound **68** showed activity against *A. niger* (MIC = 18.75 µg/mL) and *C. albicans* (MIC = 18.75 µg/mL) as compared to amphotericin B (MIC = 1.562, 6.25 µg/mL respectively against these microbes). Introduction of halogen-substituted phenyl rings significantly increased antifungal activity. Compounds **66** and **67** were most active against *B. subtilis* having MIC value of 9.375 µg/mL for each compound as compared to streptomycin (MIC = 6.25 µg/mL) [70]. Hessein and co-workers synthesized furochromone, furocoumarin and benzofuran derivatives having sulfonamide group. Upon *in vitro* evaluation, compound **69** exhibited antimicrobial potential against *E. coli* (ZOI = 20 mm) and *Aspergillus ochraceus* (ZOI = 19 mm). Compound **70** (ZOI = 19 mm) was most prominent against *E. coli* as compared to chloramphenicol (ZOI = 38 mm). Attachment of aminophenyl and biphenyl ring to the sulfonamide group significantly improved the antibacterial activity. Addition of benzotriazole or biphenyl acetamide group did not improve the antimicrobial activity [71]. Aggarwal, et al. synthesized 1,2,4-dithiazolyl derivatives as antimicrobial agents. Compound **71** showed prominent activity against *B. subtilis* (MIC = 0.78 µg/mL), *S. cerevisiae* (MIC = 6.25 µg/mL) and *C. albicans* (MIC = 3.12 µg/mL) as compared to fluconazole (MIC = 1.9 µg/mL, 3.9 µg/mL versus *S. cerevisiae*, *C. albicans*). Compound **72** presented excellent activity against *E. coli* (MIC = 1.56 µg/mL) and *B. subtilis* (MIC = 1.56 µg/mL) as compared to gentamicin (MIC = 0.9 µg/mL and 0.75 µg/mL against *E. coli* and *B. subtilis*). SAR investigation declared that substitution of the phenyl ring at 1,2,4-dithiazolyl ring is very important for antimicrobial activity and addition of the halogen atom at para-position significantly improves the activity. Addition of electron-withdrawing group e.g. chlorine and bromine at position # 6 and # 7 of chromone scaffold also enhances activity while attachment of electron-donating group e.g. methyl lowers the activity [72]. Gadhave, et al. synthesized fluorine containing pyrazolone derivatives having chromone molecule by a Knoevenagel condensation reaction [73]. Compound **75** (Fig. 9) showed prominent activity against *Streptococcus pyogenes* (MIC = 62.5 µg/mL) in comparison to ampicillin (MIC = 100 µg/mL). Compound **76** was most active against *S. aureus* having MIC value of 62.5 µg/mL. Compound **77** was most active against *P. aeruginosa* (MIC = 62.5 µg/mL) in comparison to ampicillin (MIC = 250 µg/mL). It was found that addition of propyl and trifluoromethyl group at the pyrazole ring produced potent derivatives against gram-positive bacteria [74]. Knoevenagel-cope




Fig. 8. Chromones 65 – 81 as antimicrobial agents.

condensation reaction was also used by Bari, et al. to attach chromone to isatin using thiazolidone as linker. Compounds **76** (ZOI = 47 mm) and **77** (ZOI = 40 mm) exhibited prominent activity against *S. aureus* in comparison to ciprofloxacin (ZOI = 45 mm). Derivatives in this series proved more potent against gram positive bacteria. Compound **78** was the most active antifungal agent against *A. niger* (ZOI = 22 mm) and *A. flavus* (ZOI = 25 mm) as compared to amphotericin B (ZOI = 35 mm, 30 mm against these microbes) [75]. El-Ziaty, et al. attached furanone with chromone scaffold at position # 3. Compound **79** showed moderate activity versus *E. coli* (ZOI = 13 mm) and *S. aureus* (ZOI = 15 mm) in comparison to amoxicillin (ZOI = 21 – 25 mm). Compound **79** also exhibited antifungal activity against *C. albicans* (ZOI = 10 mm) as compared to amphotericin B (ZOI = 21 mm) [76]. Nastasa, et al. conjugated chromone with 2,4-thiazolidindione through methylene group. Thiazolidindione ring was further attached with different aromatic cores. Compounds **80** and **81** presented prominent antibacterial (ZOI = 18 –

22 mm) and antifungal activity (ZOI = 18 – 22 mm) as compared to standard drug gentamicin (ZOI = 18 – 22 mm). Different concentrations were used for testing antibacterial activity and no direct relationship was observed between concentration and antibacterial activity [77].

Badhade, et al. synthesized chromone and isoxazole conjugates without any linker group. Upon *in vitro* evaluation as antibacterial agents, these derivatives exhibited excellent activity. Compounds **82** and **83** (Fig. 9) exhibited notable activities against *B. subtilis* and *S. aureus* presenting MIC values of 10 µg/mL equivalent to standard drug. Incorporation of halogen and alkyl groups in the chromone ring produced more active compounds [78]. Chromone scaffold was attached with 1,2,3-triazole by Dofe and co-workers to produce new derivatives. Compounds **84** and **85** exhibited prominent antifungal activities (MIC = 12.5 µg/mL) against *C. albicans* for both compounds as compared to miconazole (MIC = 12.5 µg/mL). Derivatives **84** and **85** showed prominent antibacterial activity (MIC = 25 µg/mL) against *B.*




Fig. 9. Chromone derivatives 82 – 90 as antimicrobial agents.

subtilis. Compound **84** bears dichloro substituted chromone skeleton while **85** consists of methyl and chlorine substituted chromone ring. Docking studies of compounds **84** and **85** with KASIII (enzyme) of *E. coli* showed scores of -4.99221 and -4.73574 respectively. Docking studies of compounds **84** and **85** with KASIII of *S. aureus* showed scores of -4.86242 and -4.82797 respectively [79]. Gholap synthesized chromone and pyrazole conjugates by the reaction of methylene group of pyrazolone with chromone-3-carbaldehyde. Compounds **86**, **87** and **88** demonstrated antimicrobial activities in this series. Compound **86** exhibited prominent activity against *S. aureus* (zone of inhibition, ZOI = 50 mm) and *E. coli* (ZOI = 40 mm) in comparison to chloramphenicol (ZOI = 44 and 38 mm against *S. aureus* and *E. coli*, respectively). Derivatives **87** and **88** were most potent against *S. albus* (ZOI = 45 mm) and *E. coli* (ZOI = 36 mm) as compared to standard drugs [80]. Less work has been reported about the antiviral activity of chromone hybrid molecules. Kim, et al. attached 3-amino-4-piperazine phenyl to the chromone core to produce new antiviral agents. Upon evaluation as antiviral agents, compound **89** was most active ($EC_{50} = 1.5 \mu\text{M}$) against hepatitis C virus but showed lower selectivity (SI = 2.6). Compound **90** presented moderate anti-SARS (severe acute respiratory syndrome) activity ($EC_{50} = 34 \mu\text{M}$) and selectivity (SI = 2.9) [81]. Ungwitayatorn, et al. synthesized 2,3-disubstituted chromone derivatives as anti-HIV agents. Compound **91** ($IC_{50} = 0.34 \mu\text{M}$, 93.16% inhibition) and **92** ($IC_{50} = 0.65 \mu\text{M}$, 92.27% inhibition) exhibited prominent anti-HIV activity as compared to standard drug pepstatin A ($91.07 \pm 1.53\%$). Molecular docking studies with HIV-1 protease showed that 3'-trifluoro-

methyl phenyl group of compound **91** interacted with hydrophobic pocket (Leu23, Val32, Val82). 3-Trifluoromethyl benzoyl group also formed hydrophobic interactions with binding site comprising Val32, Ile50, Pro81 and Val82. Hydroxyl groups of chromone scaffold interacted via hydrogen bonding with the carbonyl oxygen of Asp25 and Asp25' [8].

2.4. Chromone Derivatives as Anti-Inflammatory Agents

The process of inflammation is related to various diseases. Nonsteroidal anti-inflammatory agents are frequently used as remedy of inflammation but are associated with the major adverse effect of gastrointestinal ulceration [82]. Therefore the development of new anti-inflammatory drugs having good safety profiles is necessary. Chromone derivatives have also presented anti-inflammatory activities. Shaveta, et al. conjugated chromone with oxindole to produce new hybrid molecules. Compounds **93** ($IC_{50} = 0.029 \mu\text{M}$, SI = 46) and **94** ($IC_{50} = 0.020 \mu\text{M}$, SI = 337) (Fig. 10) were found to be most active *in vitro* inhibitors of COX-2 and also demonstrated selectivity in comparison to celecoxib ($IC_{50} = 0.04 \mu\text{M}$, SI = 375). Selectivity index of compound **94** was found equivalent to celecoxib. Compound **93** also presented analgesic activity upon *in vivo* evaluation. Docking interaction of compound **93** showed that amino and carbonyl groups of indole, as well as carbonyl oxygen of chromone, interacted with COX-2 enzyme through hydrogen bonding [83]. Venkateswararao, et al. designed and synthesized chromenone based compounds as inhibitors of interleukin-5 (IL-5). These derivatives carry cyclohexyl methoxy group at position # 5. Upon *in vitro* evaluation,




Fig. 10. Chromone derivatives **93** – **97** as anti-inflammatory agents.

compounds **95** ($IC_{50} = 4.0 \mu\text{M}$) and **96** ($IC_{50} = 6.5 \mu\text{M}$) displayed prominent activities as IL-5 inhibitors. Compounds having a hydroxyl group in the propyl chain and electron-donating functionalities at position # 4 of ring B demonstrated prominent activity. Saturation of chromone to chromane ring decreased the IL-5 inhibitory activity. Substitution of hydroxyl group in the propyl chain by keto group produced less active compounds [84]. Hatnapure, et al. synthesized chrysin containing flavonoids. Aryl group at position # 2 was replaced by n-substituted piperazine ring to produce new molecules. Derivatives in this series exhibited anti-inflammatory as well as antimicrobial activity. Compound **97** exhibited prominent inhibition of IL-6 (93% inhibition) and $TNF\alpha$ (87% inhibition) as compared to standard drug dexamethasone (71 and 84% inhibition of $TNF\alpha$ and IL-6 respectively). In compound **97**, piperazine and chromone scaffolds are separated by methylene group and piperazine is further attached to a pyrimidine. Replacement of pyrimidine ring by pyridine, p-methoxyphenyl ring produced equipotent derivatives. Substitution of pyrimidine ring by methyl, ethyl and acetyl groups produced less active derivatives [85].

2.5. Chromone Derived Molecules for Treating Alzheimer's and Other Neuronal Disorders

Alzheimer's disease (AD) is a neurological ailment mostly among the elder people and is indicated by memory loss and dementia [86]. Chromone core has been attached with various other pharmacophores to produce new multifunctional agents. Natural compounds have potential to inhibit some toxicities of Alzheimer disease [87]. Liu, et al. attached chromone-2-carboxamide with alkylbenzylamines as anti-Alzheimer agents. Compound **98** (Fig. 11) displayed excellent *in vitro* acetylcholinesterase (AChE) inhibition ($IC_{50} = 0.07 \pm 0.01 \mu\text{M}$, $SI = 735.7$) in comparison to donepezil ($IC_{50} = 0.015 \pm 0.002 \mu\text{M}$, $SI = 1380.0$). Compound **98** showed competitive as well as non-competitive inhibition. This compound also presented *in vitro* self-induced ($59.2 \pm 1.6\%$) and Cu^{+2} induced ($48.3 \pm 1.7\%$) beta-amyloid

(A β) aggregation inhibition in comparison to curcumin (self induced $43.1 \pm 1.1\%$, Cu^{+2} induced $58.0 \pm 2.3\%$). Derivatives having n-ethyl group showed better activity as compared to n-methyl group. Increase in the chain length of methylene linker also increased the activity. The compounds in this series showed weak inhibition ($IC_{50} > 20 \mu\text{M}$) of butyrylcholinesterase (BuChE). Molecular docking studies showed that chromone molecule binds with peripheral anionic site (PAS) by π - π interaction with Phe-288 and Phe-290, Phe-331 and Tyr-334 of TcAChE. Carbonyl group of chromone interacted with Tyr-121 through hydrogen bonding. Benzene ring formed π interaction with Trp-84 in the catalytic anionic site (CAS) [88]. Parveen, et al. synthesized hybrid molecules comprising chromone and chromane scaffolds. Both pharmacophores were attached to each other through Knoevenagel condensation reaction. Compound **99** was the prominent *in vitro* inhibitor ($IC_{50} = 0.27 \pm 0.3 \mu\text{M}$) of AChE as compared to tacrine ($IC_{50} = 0.19 \pm 0.03 \mu\text{M}$). Molecular modeling investigation of this derivative also showed interaction with the active site of AChE. The presence of amino group at position # 2 of chromone ring forms additional hydrogen bonding with Tyr-510 and Gly-523 of AChE. Benzene ring of chroman fragment showed π -cation interaction with Arg-522. The increased activity was also linked to the extra amino functionality in the chromone ring [18]. Hybrid molecules of 4-oxo-4H-chromene and tacrine were synthesized by Fernandez-Bachiller and colleagues in which cholinesterase inhibitory property of tacrine and antioxidant property of chromone were combined. Alkylene diamine was used as linker between these two pharmacophores and a chain of ten carbon atoms was found optimal for best activity. Hybrid proved more potent than parent drug tacrine but showed inhibition of AChE and BuChE enzymes. Compound **100** showed the most active *in vitro* inhibition of AChE ($IC_{50} = 0.035 \pm 0.001 \text{ nM}$) in comparison to standard drug tacrine ($IC_{50} = 40 \pm 2 \text{ nM}$). Compound **101** was the most active blocker of BuChE ($IC_{50} = 0.038 \pm 0.4 \text{ nM}$) as




Fig. 11. Chromone derived molecules 98 – 107 as anti-Alzheimer agents.

compared to tacrine ($IC_{50} = 10 \pm 0.4$ nM). Compound **102** presented more selectivity for AChE ($IC_{50} = 0.090 \pm 0.003$) than BuChE ($IC_{50} = 95 \pm 4$). These compound also showed good penetration ability across BBB [89]. Li, et al. attached chromone to the pharmacophoric part of clioquinol to produce multifunctional ligands. These molecules were linked together through Schiff bases. Attachment of different substituent at chromone or phenyl core produced more active compounds as compared to unsubstituted derivatives. Compound **103** presented an effective inhibition of MAO-A ($IC_{50} = 5.12$ μ M) and MAO-B ($IC_{50} = 0.816$ μ M) in comparison to standard drug iproniazide (MAO-A $IC_{50} = 6.46 \pm 0.5$ μ M, MAO-B $IC_{50} = 7.98 \pm 0.37$ μ M). Compound **103** possesses potential anti-Alzheimer activity as it showed anti-oxidant activity (ORAC = 3.62), capacity to penetrate BBB and moderate inhibition (75.1% at the dose of 20 μ M) of $A\beta$ aggregation. Attachment of methyl group at the position # 6 of chromone produced more active derivatives. Replacement of phenyl ring by naphthalene or pyridine ring produced less active derivatives. Docking studies with MAO revealed that chromone part of **103** formed π - π interaction with Phe-208 while the carbonyl group interacted with Gln-215.

2-Amino-4-methyl phenol group occupied the hydrophobic pocket formed by Leu-171, Ile-198 and Ile-199 [90]. Mackhaeva, et al. synthesized 2-vinyl chromone derivatives as selective butyryl cholinesterase (BuChE) inhibitors. Derivatives having n-benzyl and n-vinyl methoxy carbonyl substituted compounds presented more selectivity for BuChE. In this series, compound **104** appeared as the most potent inhibitor ($IC_{50} = 2.27 \pm 0.18$ μ M) of BuChE in comparison to tacrine ($IC_{50} = 0.0290 \pm 0.0002$ μ M). Compound **104** carry bromine atom at position # 6 of chromone core. Introduction of ethoxy group at position # 8 of chromone core produced less active derivatives. Molecular docking studies showed that methoxy carbonyl group interacted with anionic site formed by Gly116, Gly117 and Ala199. The n-benzyl group interacted with Tyr440 and Trp430 and showed more affinity (binding free energy = 1.5 kcal/mol) as compared to n-methyl substituent at this position [91]. Cagide and co-workers synthesized chromone-2-phenyl carboxamide derived compounds as adenosine A1 (hA1) receptor ligands. Different substituents were attached at the exocyclic phenyl ring. Compound **105** presented prominent activity at hA1 ($ki=0.219$ μ M) receptor and this compound also exhibited




Fig. 12. Chromone derivatives 108 – 117 as antioxidant agents.

selectivity for this receptor as compared to hA3. It bears nitro group at ortho position of phenyl ring. Shifting of nitro group at meta or para position produced less active derivatives. Authors explained that receptor sites of hA1 (lined by Asn170, Glu170, Glu172 and Thr270) and hA3 (Ser73, Gln167, Val169, Leu264) are different from each other. These derivatives also follow Lipinski rule of five and possess drug like properties [92]. Ali Abid, et al. synthesized sulfonyl hydrazone derivatives of 3-formyl chromones as monoamine oxidase (MAO) inhibitors. These compounds showed capacity to inhibit MAO-A and MAO-B enzymes simultaneously. Compound **106** was the most active ($IC_{50} = 0.33 \pm 0.01 \mu\text{M}$) *in vitro* MAO-A inhibitor in comparison to clorgyline ($IC_{50} = 0.004 \pm 0.0003 \mu\text{M}$). It bears chlorine atom at position # 6 of chromone skeleton. Replacement of chlorine by methyl group produced less active derivatives. Compound **107** was the most active ($IC_{50} = 1.12 \pm 0.02 \mu\text{M}$) MAO-B inhibitor as compared to deprenyl ($IC_{50} = 0.0196 \pm 0.001 \mu\text{M}$). It carries fluorine atom at position # 6 and replacement of fluorine atom by chlorine or bromine atom produced less active derivatives. Molecular docking studies of compound **107** with MAO-B showed that sulfonamide oxygen interacted by hydrogen bonding with Tyr60. Oxygen atoms of chromone ring

and carbonyl group interacted through hydrogen bonding with Gln206 and Tyr435. Derivatives in this series exhibited good pharmacokinetic properties such as oral bioavailability [93].

2.6. Antioxidant Agents Having Chromone Scaffold

Reactive oxygen species produce oxidative damage to various biomolecules. Naturally occurring compounds have also displayed antioxidant activities [94]. Chromone derivatives also play significant role as antioxidants and free radical scavengers [95]. Berczynski, et al. (2013) evaluated chromone conjugated derivatives of 2,4-thiazolidinedione, 2,4-imidazolidinedione, 2-thioxo-imidazolidine-4-one as antioxidant agents. Derivatives having 2-thioxo-imidazolidine scaffold exhibited prominent activity against $\text{OH}\cdot$, DPPH-free radicals. Compound **108** (Fig. 12) appeared as the most active *in vitro* free radical scavenger ($IC_{50} = 0.353 \pm 0.04 \text{ mmol/L}$) in comparison to standard drug tiron ($IC_{50} = 0.451 \pm 0.065 \text{ mmol/L}$). In compound **108**, 2, 3-double of chromone is in conjugation with the 4-carbonyl group and this is the reason for increased antioxidant activity [96]. Berczynskai, et al. (2013) evaluated chromone molecules having 2,4-thiazolidinedione and 2,4-imidazolidinedione

heterocyclic rings for antioxidant activities. Heterocyclic rings were further attached with substituted aromatic rings. In DPPH (1,1-diphenyl-2-picryl-hydrazyl) radical scavenging assay, compounds **109** ($IC_{50} = 194 \pm 3.5 \mu\text{mol/L}$) and **110** ($IC_{50} = 364 \pm 3.3 \mu\text{mol/L}$) presented prominent activity as compared to vitamin C ($IC_{50} = 346 \pm 28 \mu\text{mol/L}$). By using the DMPO-OH (5,5-dimethyl-1-pyrroline-1-oxide) spin adduct method, **109** (41.7% inhibition) and **110** (35.1% inhibition) also exhibited free radical scavenging activity [97]. Takao and colleagues synthesized 3-styryl chromone derivatives by Konevangel reaction as α -glucosidase inhibitor and as antioxidant agents. Compounds **111** ($EC_{50} = 17 \mu\text{M}$) and **112** ($EC_{50} = 23 \mu\text{M}$) showed prominent *in vitro* activities as DPPH scavenger as compared to ascorbic acid ($EC_{50} = 23 \mu\text{M}$). Compounds **111** ($IC_{50} = 16 \mu\text{M}$) and **112** ($IC_{50} = 10 \mu\text{M}$) also exhibited inhibition of α -glucosidase enzyme. Both compounds contain catechol ring attached to the chromone scaffold. SAR studies showed that incorporation of methyl group and halogen atoms on the ring **B** did not increase the activity but the incorporation of hydroxyl group produced active molecules. Dihydroxy derivatives showed better activity as compared to monohydroxy derivatives. [98]. Proenca, et al. attached chromone with 3,4-dihydroxy phenyl core via 1,3-diene system. Compound **113** ($IC_{50} = 125 \pm 13 \mu\text{M}$) and **114** ($IC_{50} = 121 \pm 9 \mu\text{M}$) showed prominent activity as scavenger of hydrogen peroxide (H_2O_2) as compared to standard drug quercetin ($IC_{50} = 1338 \pm 42 \mu\text{M}$). Compound **114** also exhibited effective scavenging of HOCl ($IC_{50} = 17 \pm 3 \mu\text{M}$), $\text{ROO}\cdot$ and ONOO^- ($IC_{50} = 0.29 \pm 0.02 \mu\text{M}$). Incorporation of hydroxyl groups both at position # 5 and # 7 of chromone scaffold was important for the antioxidant activity. No prominent difference in the activity was observed for these hydroxyl groups [99]. Soengas, et al. synthesized chromone-3-pyrazoly derivatives as free radical scavenger and alpha glucosidase inhibitor. Compound **115** appeared as the most effective antioxidant agent ($IC_{50} = 23 \mu\text{M}$) as compared to standard drug α -tocopherol ($IC_{50} = 23 \mu\text{M}$). It possesses catechol group in its structure and it proved more active as compared to monohydroxyl derivatives. Addition of hydroxyl group in the chromone ring had no significant influence on the activity [100]. Rao, et al. synthesized styryl chromone derivatives in which styryl group was attached at position # 2 of chromone core. Antioxidant activity was monitored as scavenger of superoxide free radical. Antioxidant activity was dependent on the number of hydroxyl groups, and compound **116** emerged as the most active agent ($IC_{50} = 234 \mu\text{M}$) in comparison to vitamin C ($IC_{50} = 852 \mu\text{M}$). Compound **116** also showed excellent antibacterial activity against *Xanthomonas campestris* (ZOI = 11.3 mm) and *Agarobacterium tumefaciens* (ZOI = 11 mm) as compared to streptomycin (ZOI = 12 – 15 mm). Chromone derivatives having hydroxyl group also presented better antimicrobial activity. Replacement of hydroxyl group with methoxy group decreased antibacterial activity and increased

antifungal activity [101]. Demetgül and co-workers linked chromone with chitosan to produce the chromone-chitosan Schiff base. Upon *in vitro* evaluation as antioxidant agent by DPPH radical scavenging assay, compound **117** emerged as the most potent ($IC_{50} = 0.88 \text{ mg/mL}$) antioxidant agent as compared to chitosan alone. The increased antioxidant activity was related to the phenolic group present in chromone [102].

Thus, chromone is a promising scaffold for the synthesis of new therapeutic agents, and hybrid molecules presented in this review can be used as lead for future drug discovery.

REFERENCES

1. J. R. S. Hoult, M. A. Moroney, and M. Paya, *Actions of Flavonoids and Coumarins on Lipoxygenase and Cyclooxygenase*, Academic Press (1994), pp. 443 – 454.
2. A. S. Bhat, J. L. Whetstone, and R. W. Brueggemeier, *Tetrahedron Lett.*, **40**(13), 2469 – 2472 (1999).
3. T. Al Nakib, V. Bezjak, M. Meegan, et al., *Eur. J. Med. Chem.*, **25**(5), 455 – 462 (1990).
4. M. Isaka, M. Sappan, P. Auncharoen, et al., *Phytochem. Lett.*, **3**(3), 152 – 155 (2010).
5. S. V. Jovanovic, S. Steenken, M. Tosic, et al., *J. Am. Chem. Soc.*, **116**(11), 4846 – 4851 (1994).
6. M. Kidwai, S. Saxena, M. K. R. Khan, et al., *Bioorg. Med. Chem. Lett.*, **15**(19), 4295 – 4298 (2005).
7. R. Larget, B. Lockhart, P. Renard, et al., *Bioorg. Med. Chem. Lett.*, **10**(8), 835 – 838 (2000).
8. J. Ungwitayatorn, C. Wiwat, W. Samee, et al., *JMoSt*, **1001**(1 – 3), 152 – 161 (2011).
9. N. Desideri, P. Mastromarino, and C. Conti, *Antiviral Chem. Chemother.*, **14**(4), 195 – 203 (2003).
10. P. J. Houghton, T. Z. Woldemariam, A. I. Khan, et al., *Antiviral Res.*, **25**(3), 235 – 244 (1994).
11. W. Huang, Y. Ding, Y. Miao, et al., *Eur. J. Med. Chem.* **44**(9), 3687 – 3696 (2009).
12. M. Mazzei, A. Balbi, E. Sottofattori, et al., *Eur. J. Med. Chem.* **28**(9), 669 – 674 (1993).
13. D. H. Nam, K. Y. Lee, C. S. Moon, et al., *Eur. J. Med. Chem.* **45**(9), 4288 – 4292 (2010).
14. S.-T. Chung, W.-H. Huang, C.-K. Huang, et al., *Res. Chem. Intermed.* **42**(2), 1195 – 1215 (2016).
15. S. Kirkiacharian, H. G. Tongo, J. Bastide, et al., *Eur. J. Med. Chem.* **24**(5), 541 – 546 (1989).
16. N. S. Parmar, M. Tariq, and A. M. Ageel, *Res. Commun. Chem. Pathol. Pharmacol.* **58**(1), 15 – 25 (1987).
17. D. A. Horton, G. T. Bourne, and M. L. Smythe, *Chem. Rev.*, **103**(3), 893 – 930 (2003).
18. M. Parveen, A. M. Malla, Z. Yaseen, et al., *J. Photochem. Photobiol. B: Biol.*, **130**(179 – 187) (2014).
19. A. Nohara, T. Umetani, and Y. Sanno, *Tetrahedron Lett.*, **14**(22), 1995 – 1998 (1973).
20. S. Byrappa, M. H. Raj, T. Kungyal, et al., *Eur. J. Med. Chem.*, **126**(218 – 224) (2017).
21. D. J. Newman, G. M. Cragg, and K. M. Snader, *J. Nat. Prod.*, **66**(7), 1022 – 1037 (2003).
22. H. K. Koul, M. Pal, and S. Koul, *Genes.Cancer*, **4**(9 – 10), 342 – 359 (2013).
23. K. M. Amin, Y. M. Syam, M. M. Anwar, et al., *Bioorg. Chem.*, **76**(487 – 500) (2018).

24. P. Singh, M. Kaur, and W. Holzer, *Eur. J. Med. Chem.*, **45**(11), 4968 – 4982 (2010).
25. F. M. Awadallah, T. A. El-Waei, M. M. Hanna, et al., *Eur. J. Med. Chem.*, **96**(425 – 435 (2015)).
26. Q.-H. Chen, K. Yu, X. Zhang, et al., *Bioorg. Med. Chem. Lett.*, **25**(20), 4553 – 4556 (2015).
27. Z. Dolatkah, S. Javanshir, A. S. Sadr, et al., *J. Chem. Inf. Model.*, **57**(6), 1246 – 1257 (2017).
28. D. H. Nam, K. Y. Lee, C. S. Moon, et al., *Eur. J. Med. Chem.*, **45**(9), 4288 – 4292 (2010).
29. R. K. Bhatia, L. Singh, R. Garg, et al., [Please refine].
30. C. Ozen, M. Ceylan-Unlusoy, M. Ozturk, et al., *Med. Chem. Res.*, **27**(1), 153 – 160 (2018).
31. B. Singh, V. Sharma, G. Singh, et al., *Int. J. Med. Chem.*, **2013** (2013).
32. J. E. Obrique-Balboa, Q. Sun, G. Bernhardt, et al., *Eur. J. Med. Chem.*, **109**, 124 – 133 (2016).
33. O. M. Abdelhafez, K. M. Amin, H. I. Ali, et al., *RSC Adv.*, **4**(23), 11569 – 11579 (2014).
34. K. Chand, R. K. Tiwari, S. Kumar, et al., *J. Heterocycl. Chem.*, **52**(2), 562 – 572 (2015).
35. S. H. Han, S. Kim, U. De, et al., *J. Org. Chem.*, **81**(24), 12416 – 12425 (2016).
36. F. Bousejra-ElGarah, B. Lajoie, J.-P. Souchard, et al., *Med. Chem. Res.*, **25**(11), 2547 – 2556 (2016).
37. T. E. Ali, M. A. Ibrahim and S. M. El-Edfawy, *Phosphorus, Sulphur, Silicon Relat. Elem.*, **192**(7), 819 – 826 (2017).
38. C. Sun, C. Chen, S. Xu, et al., *Biorg. Med. Chem.*, **24**(16), 3862 – 3869 (2016).
39. M. N. Abu-Aisheh, M. S. Mustafa, M. M. El-Abadelah, et al., *Eur. J. Med. Chem.*, **54**(65 – 74 (2012)).
40. G. Singh, A. Kaur, V. Sharma, et al., *Med. Chem. Comm.*, **4**(6), 972 – 978 (2013).
41. S. Singh, A. Chopra, G. Singh, et al., *J. Pharm. Res.*, **7**(4), 337 – 341 (2013).
42. C. Zwergel, S. Valente, A. Salvato, et al., *Med. Chem. Comm.*, **4**(12), 1571 – 1579 (2013).
43. J. Rodon, R. Dienstmann, V. Serra, et al., *Nature Rev. Clin. Oncol.*, **10**(3), 143 (2013).
44. W. Zhu, C. Chen, C. Sun, et al., *Eur. J. Med. Chem.*, **93**, 64 – 73 (2015).
45. World Health Organization (2017); <http://www.who.int/mediacentre/factsheets/fs138/en/>.
46. B. B. Zhang and D. E. Moller, *Curr. Opin. Chem. Biol.*, **4**(4), 461 – 467 (2000).
47. M. Ceylan-Ünlüsoy, E. J. Verspohl, and R. Ertan, *J. Enzyme Inhib. Med. Chem.*, **25** (6), 784 – 789 (2010).
48. M. C. Unlusoy, C. Kazak, O. Bayro, et al., *J. Enzyme Inhib. Med. Chem.*, **28**(6), 1205 – 1210 (2013).
49. G. Wang, M. Chen, J. Wang, et al., *Bioorg. Med. Chem. Lett.*, **27**(13), 2957 – 2961 (2017).
50. G. Wang, M. Chen, J. Qiu, et al., *Bioorg. Med. Chem. Lett.*, **28**(2), 113 – 116 (2018).
51. U. Salar, K. M. Khan, S. Chigurupati, et al., *Sci. Rep.*, **7**(1), 16980 (2017).
52. P. Valentina, K. Ilango, S. Chander, et al., *Bioorg. Chem.*, **74**, 158 – 165 (2017).
53. D. M. Morens, G. K. Folkers, and A. S. Fauci, *Nature*, **430**(6996), 242 (2004).
54. P. K. Bathini, H. Yerrabelly, and J. R. Yerrabelly, *Org. Chem.*, (Part 3), 212 – 228 (2018).
55. J. C. Coa, E. García, M. Carda, et al., *Med. Chem. Res.*, **26**(7), 1405 – 1414 (2017).
56. E. García, J. C. Coa, E. Otero, et al., *Med. Chem. Res.*, **27**(2), 497 – 511 (2018).
57. E. Otero, S. Vergara, S. M. Robledo, et al., *Molecules*, **19**(9), 13251 – 13266 (2014).
58. P. Lerdsirisuk, C. Maicheen, and J. Ungwitayatorn, *Bioorg. Chem.*, **57**, 142 – 147 (2014).
59. H. C. Kolb, M. Finn, and K. B. Sharpless, *Angew. Chem. Int. Ed.*, **40**(11), 2004 – 2021 (2001).
60. C. A. Lipinski, F. Lombardo, B. W. Dominy, et al., *Adv. Drug Del. Rev.*, **23**(1 – 3), 3 – 25 (1997).
61. V. Nalla, A. Shaikh, S. Bapat, et al., *Royal Soc. Open Sci.* **5**(4), 171750 (2018).
62. A. Singh, D. Bimal, R. Kumar, et al., *Synth. Commun.* **48**(18), 2339 – 2346 (2018).
63. S. Bräse, C. Gil, K. Knepper, et al., *Angew. Chem. Int. Ed.*, **44**(33), 5188 – 5240 (2005).
64. P. A. Cano, A. Islas-Jácome, Á. Rangel-Serrano, et al., *Molecules* **20**(7), 12436 – 12449 (2015).
65. M. U. Reddy, M. S. Reddy, and V. Chakravartula, *Asian. J. Res. Chem.*, **11**(1), 55 – 60 (2018).
66. B. Pouramiri, E. T. Kermani, and M. Khaleghi, *J. Iran. Chem. Soc.*, **14**(11), 2331 – 2337 (2017).
67. S. V. Tiwari, J. A. Seijas, M. P. Vazquez-Tato, et al., *Molecules*, **23**(2), 440 (2018).
68. W. Li, J. Li, H. Shen, et al., *Chin. Chem. Lett.*, **29**(6), 911 – 914 (2018).
69. Z. N. Siddiqui, S. Praveen, and F. Farooq, *Chem. Papers*, **64**(6), 818 – 824 (2010).
70. K. Battula, S. Narsimha, V. R. Nagavelli, et al., *J. Serb. Chem. Soc.*, **81**, 88 – 88 (2016).
71. S. A. Hessein, M. A. El-Sharief, S. Y. Abbas, et al., *Croat. Chem. Acta*, **89**(1), 91 – 100 (2016).
72. N. Aggarwal, V. Sharma, H. Kaur, et al., *Int. J. Med. Chem.*, **2013** ((2013)).
73. E. Knoevenagel, *Ber. Deutsch. Chem. Gesellschaft*, **31**(3), 2596 – 2619 (1898).
74. A. Gadhav, S. Kuchekar, and B. Karale, *J. Chem.*, **2013** ((2012)).
75. A. Bari, S. Ali, A. Kadi, et al., *Chem. Heterocycl. Comp.*, **49**(12), 1723 – 1731 (2014).
76. A. K. El-Ziaty, W. S. Abou-Elmagd, S. K. Ramadan, et al., *Synth. Commun.*, **47**(5), 471 – 480 (2017).
77. C. M. Nastasă, M. Duma, A. Pîrnău, et al., *Cluj. Med.*, **89**(1), 122 (2016).
78. P. Badadhe, L. Patil, S. Bhagat, et al., *J. Heterocycl. Chem.*, **50**(5), 999 – 1004 (2013).
79. V. S. Dofe, A. P. Sarkate, D. K. Lokwani, et al., *Res. Chem. Intermed.*, **43**(1), 15 – 28 (2017).
80. S. S. Gholap, *Heterocycl. Lett.*, **2**(4), 461 – 466 (2012).
81. M. K. Kim, H. Yoon, D. L. Barnard, et al., *Chem. Pharm. Bull.*, **61**(4), 486 – 488 (2013).
82. J. M. Cash and J. H. Klippel, *New Engl. J. Med.*, **330**(19), 1368 – 1375 (1994).
83. Shaveta, A. Singh, M. Kaur, et al., *Eur. J. Med. Chem.*, **77**, 185 – 192 (2014).
84. E. Venkateswararao, V. K. Sharma, K.-C. Lee, et al., *Bioorg. Med. Chem.*, **21**(9), 2543 – 2550 (2013).
85. G. D. Hatnapure, A. P. Keche, A. H. Rodge, et al., *Bioorg. Med. Chem. Lett.*, **22**(20), 6385 – 6390 (2012).
86. M. Townsend, *J. Alzheimer's Dis.*, **24**(s2), 43 – 52 (2011).
87. H. Kim, B.-S. Park, K.-G. Lee, et al., *J. Agric. Food Chem.*, **53**(22), 8537 – 8541 (2005).
88. Q. Liu, X. Qiang, Y. Li, et al., *Bioorgan. Med. Chem.*, **23**(5), 911 – 923 (2015).

89. M. I. Fernandez-Bachiller, C. n. Peirez, L. Monjas, et al., *J. Med. Chem.*, **55**(3), 1303 – 1317 (2012).
90. F. Li, J.-J. Wu, J. Wang, et al., *Bioorg. Med. Chem.*, **25**(14), 3815 – 3826 (2017).
91. G. F. Makhaeva, N. P. Boltneva, S. V. Lushchekina, et al., *Bioorg. Med. Chem.*, **26**(16), 4716 – 4725 (2018).
92. F. Cagide, J. Reis, A. Gaspar, et al., *RSC Adv.*, **6**(52), 46972 – 46976 (2016).
93. S. M. A. Abid, H. A. Younus, M. Al-Rashida, et al., *Bioorg. Chem.*, **75**, 291 – 302 (2017).
94. M. Valko, D. Leibfritz, J. Moncol, et al., *The Int. J. Biochem. Cell Biol.*, **39**(1), 44 – 84 (2007).
95. P. Yadav, B. Parshad, P. Manchanda, et al., *Curr. Top. Med. Chem.*, **14**(22), 2552 – 2575 (2014).
96. P. Berczyński, E. Duchnik, I. Kruk, et al., *Luminescence*, **29**(4), 367 – 373 (2014).
97. P. Berczyński, A. Kładna, I. Kruk, et al., *J. Flu.*, **23**(6), 1319 – 1327 (2013).
98. K. Takao, R. Ishikawa and Y. Sugita, *Chem. Pharm. Bull.*, **62**(8), 810 – 815 (2014).
99. C. Proença, H. M. Albuquerque, D. Ribeiro, et al., *Eur. J. Med. Chem.*, **115**, 381 – 392 (2016).
100. R. G. Soengas, V. L. Silva, D. Ide, et al., *Tetrahedron*, **72**(23), 3198 – 3203 (2016).
101. M. Rao, B. Ujwala, P. Priyadarshini, et al., *Der. Pharma. Chemica*, **8**(7), 1 – 6 (2016).
102. C. Demetgül and N. Beyazit, *Carbohydr. Polym.*, **181**, 812 – 817 (2018).